Fingerprint
Dive into the research topics of 'Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically